HTL Biotechnology
Lixin Dai is a distinguished biotechnology leader currently serving as Senior Director of Biotechnology Innovation at HTL Biotechnology since May 2024. Previously, Lixin held various senior roles at Modern Meadow from November 2014 to April 2024, including Senior Director of Biotechnology and Director of Cell Engineering, where responsibilities encompassed strategic planning, intellectual property management, and project oversight across multiple scientific disciplines. With a strong academic background, including a Ph.D. from the University of Calgary and a Bachelor of Science from Nankai University, Lixin has extensive experience in cellular engineering, high-throughput screening, and synthetic biology, gained through significant research roles at Johns Hopkins University School of Medicine.
This person is not in any offices
HTL Biotechnology
HTL is the world leader in the development and production of pharmaceutical grade biopolymers used to develop life-changing treatments for millions of patients. A pioneer in the bioproduction of hyaluronic acid, HTL has developed and refined for over 30 years its innovative functional biopolymer platform that has enabled it to produce "customised" pharmaceutical grade products for the leaders of the pharmaceutical and medical devices sectors in therapeutic areas such as ophthalmology, dermatology, medical aesthetics, rheumatology and urology Thanks to its dedicated R&D team, its partnerships and its incubator, HTL is now driving innovation in the biopolymer sector. Its R&D strategy aims to address unmet medical needs by creating new types of biopolymers, modifying their physico-chemical properties, and exploring new medical applications in cutting-edge areas such as bioprinting and drug delivery. very.